Table 1.
Univariate analyses of ST131 and non-ST131 clones in patients with ESBL E. coli bacteremia
| Characteristic | No. (%) of patientsa |
OR (95% CI) | Univariate P value | |
|---|---|---|---|---|
| ST131 (n = 36) | Non-ST131 (n = 86) | |||
| Mean patient age (in yrs) ± SD (range) | 64 ± 15.2 (27–86) | 64.4 ± 16.8 (23–91) | 1.00 (0.98–1.02) | 0.905 |
| Males | 21 (58.3) | 43 (50.0) | 1.40 (0.64–3.07) | 0.401 |
| Elderly patients | 20 (55.6) | 50 (58.1) | 0.90 (0.41–1.97) | 0.792 |
| Comorbid conditions | ||||
| Diabetes mellitus | 12 (33.3) | 25 (29.1) | 1.22 (0.53–2.81) | 0.640 |
| Cancer | 10 (27.8) | 24 (27.9) | 0.99 (0.42–2.37) | 0.988 |
| Chronic hepatitis/cirrhosis | 5 (13.9) | 29 (30.2) | 0.37 (0.13–1.06) | 0.065 |
| Congestive heart failure | 19 (52.8) | 41 (47.7) | 1.23 (0.56–2.67) | 0.607 |
| Cardiovascular disease | 10 (27.8) | 23 (26.7) | 1.05 (0.44–2.52) | 0.907 |
| Dementia | 1 (2.8) | 7 (8.1) | 0.32 (0.04–2.72) | 0.298 |
| Chronic obstructive pulmonary disease | 4 (11.1) | 12 (14) | 0.77 (0.23–2.57) | 0.672 |
| End-stage renal disease | 2 (5.6) | 9 (10.5) | 0.50 (0.10–2.45) | 0.396 |
| Charlson comorbidity score of <3 | 6 (16.7) | 10 (11.6) | 1.52 (0.51–4.55) | 0.454 |
| Primary bacteremia | 2 (5.6) | 19 (22.1) | 0.21 (0.05–0.94) | 0.042 |
| Secondary bacteremia | ||||
| Pneumonia | 1 (2.8) | 5 (5.8) | 0.46 (0.05–4.11) | 0.489 |
| Skin and soft tissue infection | 1 (2.8) | 3 (3.5) | 0.79 (0.08–7.86) | 0.841 |
| Surgical site infection | 2 (5.6) | 1 (1.2) | 5.00 (0.44–56.98) | 0.195 |
| Central-line-associated infection | 3 (8.3) | 3 (3.5) | 2.52 (0.48–23.10) | 0.273 |
| Biliary tract infection | 5 (13.9) | 11 (12.8) | 1.10 (0.35–3.43) | 0.870 |
| Intraabdominal infection | 1 (2.8) | 5 (5.8) | 0.46 (0.05–4.11) | 0.489 |
| Urinary tract infection, not catheter associated | 20 (55.6) | 27 (31.4) | 2.73 (1.23–6.08) | 0.014 |
| Health care-associated risk in prior 3 months | ||||
| Community onset | 21 (58.3) | 44 (51.2) | 1.34 (0.61–2.93) | 0.470 |
| No antibiotic use | 15 (41.7) | 21 (24.4) | 2.21 (0.97–5.05) | 0.060 |
| Fluoroquinolone use | 10 (27.8) | 19 (22.1) | 1.36 (0.56–3.30) | 0.502 |
| Cephalosporin use | 19 (52.8) | 55 (64) | 0.59 (0.27–1.27) | 0.177 |
| Operation | 10 (27.8) | 24 (27.9) | 0.99 (0.42–2.37) | 0.988 |
| Hospitalization | 21 (58.3) | 41 (47.7) | 1.54 (0.70–3.37) | 0.284 |
| Nasogastric tube use | 9 (25) | 25 (29.1) | 0.813 (0.34–1.97) | 0.648 |
| Central catheter use | 6 (16.7) | 13 (15.1) | 1.12 (0.39–3.23) | 0.830 |
| Urinary catheter use | 4 (11.1) | 24 (27.9) | 0.32 (0.10–1.01) | 0.052 |
a
Values are the numbers and percentages of patients unless otherwise noted.